RU2131260C1 - Preparation for treatment of patients with gastroenteric diseases - Google Patents
Preparation for treatment of patients with gastroenteric diseases Download PDFInfo
- Publication number
- RU2131260C1 RU2131260C1 RU98118559A RU98118559A RU2131260C1 RU 2131260 C1 RU2131260 C1 RU 2131260C1 RU 98118559 A RU98118559 A RU 98118559A RU 98118559 A RU98118559 A RU 98118559A RU 2131260 C1 RU2131260 C1 RU 2131260C1
- Authority
- RU
- Russia
- Prior art keywords
- preparation
- lactulose
- treatment
- patients
- drug
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Изобретение относится к практической медицине, а именно к препаратам для лечения желудочно-кишечных, онкологических, аллергических заболеваний, нарушений жирового обмена, вирусного и хронического гепатита, атеросклероза, подагры, артроза, остеохондроза, дисбактериоза, а также общих интоксикаций любой природы. The invention relates to practical medicine, namely to preparations for the treatment of gastrointestinal, oncological, allergic diseases, disorders of fat metabolism, viral and chronic hepatitis, atherosclerosis, gout, arthrosis, osteochondrosis, dysbiosis, as well as general intoxications of any nature.
Известно использование в качестве препарата для лечения желудочно-кишечных и других заболеваний щелочного гидролизного лигнина (а.с. СССP N 910186, Б.И. N 28, 1983 г). Known use as a drug for the treatment of gastrointestinal and other diseases of alkaline hydrolytic lignin (A.C. CCCP N 910186, B.I. N 28, 1983).
Недостатком этого препарата является то, что он наряду с болезнетворными бактериями, токсинами, радионуклидами, тяжелыми металлами, шлаками и др. сорбирует и выводит из кишечника положительные микроорганизмы - сапрофиты, бифидобактерии и лактобактерии, сопровождающие человека в процессе его жизнедеятельности, т.е. имеет место так называемое влияние энтеросорбента. The disadvantage of this drug is that, along with pathogenic bacteria, toxins, radionuclides, heavy metals, slags, etc., it absorbs and removes positive microorganisms from the intestines - saprophytes, bifidobacteria and lactobacilli that accompany a person during his life, i.e. the so-called effect of enterosorbent takes place.
Задачей изобретения является улучшение лечебных свойств препарата. The objective of the invention is to improve the healing properties of the drug.
Предлагается препарат для лечения желудочно-кишечных и иных заболеваний, содержащий щелочной гидролизный лигнин, и дополнительно лактулозу при следующем соотношении компонентов, мас.%:
Щелочной гидролизный лигнин - 60 - 90
Лактулоза - 10 - 40
Кроме указанных компонентов новый препарат может содержать, например, гидроцеллюлозу, минеральные вещества.A preparation is proposed for the treatment of gastrointestinal and other diseases, containing alkaline hydrolysis lignin, and additionally lactulose in the following ratio of components, wt.%:
Alkaline hydrolysis lignin - 60 - 90
Lactulose - 10 - 40
In addition to these components, the new drug may contain, for example, hydrocellulose, minerals.
Отличиями предлагаемого препарата от прототипа являются дополнительное содержание лактулозы и указанное соотношение компонентов. The differences of the proposed drug from the prototype are the additional content of lactulose and the specified ratio of components.
При этом вследствие точечной (дозированной) доставки питательной среды (лактулозы) на очищенную от токсинов слизистую ткань с оставшимися лакто- и бифидобактериями эти бактерии бурно развиваются. В случае отдельного использования лактулозы такого эффекта не наблюдается, очевидно, вследствие нейтрализации и разложения большей части лактулозы токсинами, солями тяжелых металлов и т.д. Повышенный рост положительных сапрофитов дает толчок оздоровлению организма в целом. In this case, due to the point (dosed) delivery of the nutrient medium (lactulose) to the mucous tissue cleared of toxins with the remaining lacto- and bifidobacteria, these bacteria are rapidly developing. In the case of separate use of lactulose, this effect is not observed, obviously, due to the neutralization and decomposition of most of the lactulose by toxins, salts of heavy metals, etc. The increased growth of positive saprophytes gives an impetus to the healing of the body as a whole.
Пример 1. У здоровой взрослой морской свинки массой 300 г проводят исследование микрофлоры кишечника посредством выделения из испражнений аутоштаммов бифидобактерий и лактобактерий по стандартной методике. Example 1. In a healthy adult guinea pig weighing 300 g, the intestinal microflora is examined by isolating bifidobacteria and lactobacilli from the stool of autostrains using standard methods.
Начиная со следующего дня после проведения предварительного исследования микрофлоры кишечника, животное в течение 10 дней получало препарат состава, мас.%:
Щелочной гидролизный лигнин - 60
Лактулоза - 40
в количестве 10 г/кг массы тела. Препарат был получен путем добавления в сироп лактулозы, нагретый до 45 - 50oC, мелкодисперсного щелочного гидролизного лигнина и перемешивания массы высокоскоростной мешалкой.Starting from the day after a preliminary study of the intestinal microflora, the animal for 10 days received the drug composition, wt.%:
Alkaline hydrolysis lignin - 60
Lactulose - 40
in the amount of 10 g / kg of body weight. The preparation was obtained by adding lactulose, heated to 45-50 ° C, finely divided alkaline hydrolysis lignin to the syrup and mixing the mass with a high-speed mixer.
Исходный уровень бифидобактерий в толстом кишечнике у морской свинки составлял 3,0 х 104 клеток на 1 г. На десятый день после принятия препарата количество бифидобактерий увеличилось до 1,5 х 106 клеток на 1 г.The initial level of bifidobacteria in the colon of the guinea pig was 3.0 x 10 4 cells per 1 g. On the tenth day after taking the drug, the number of bifidobacteria increased to 1.5 x 10 6 cells per 1 g.
Исходное количество лактобактерий составляло 2,6 х 104 клеток на 1 г. После анализа на десятый день количество лактобактерий повысилось до 1,2 х 106 клеток на 1 г. При этом микрофлора тонкого кишечника оставалось в пределах нормы.The initial number of lactobacilli was 2.6 x 10 4 cells per 1 g. After analysis on the tenth day, the number of lactobacilli increased to 1.2 x 10 6 cells per 1 g. At the same time, the microflora of the small intestine remained within normal limits.
Пример 2. Исследование проводилось аналогично примеру 1 с использованием препарата состава, мас.%:
Щелочной гидролизный лигнин - 90
Лактулоза - 10
При таком же исходном уровне бифидобактерий и лактобактерий, как в примере 1, на десятый день после принятия препарата число бифидобактерий увеличилось до 1,4 х 106 клеток на 1 г, а число лактобактерий - до 1,8 х 105 клеток на 1 г.Example 2. The study was carried out analogously to example 1 using the drug composition, wt.%:
Alkaline hydrolysis lignin - 90
Lactulose - 10
With the same initial level of bifidobacteria and lactobacilli, as in example 1, on the tenth day after taking the drug, the number of bifidobacteria increased to 1.4 x 10 6 cells per 1 g, and the number of lactobacilli - up to 1.8 x 10 5 cells per 1 g .
При этом микрофлора тонкого кишечника оставалась в пределах нормы. At the same time, the microflora of the small intestine remained within normal limits.
Claims (1)
Щелочной гидролизный лигнин - 60 - 90
Лактулоза - 10 - 40A preparation for the treatment of gastrointestinal diseases, containing alkaline hydrolytic lignin, characterized in that it additionally contains lactulose in the following ratio of components, wt.%:
Alkaline hydrolysis lignin - 60 - 90
Lactulose - 10 - 40
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU98118559A RU2131260C1 (en) | 1998-10-14 | 1998-10-14 | Preparation for treatment of patients with gastroenteric diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU98118559A RU2131260C1 (en) | 1998-10-14 | 1998-10-14 | Preparation for treatment of patients with gastroenteric diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2131260C1 true RU2131260C1 (en) | 1999-06-10 |
Family
ID=20211204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU98118559A RU2131260C1 (en) | 1998-10-14 | 1998-10-14 | Preparation for treatment of patients with gastroenteric diseases |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2131260C1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011037495A1 (en) * | 2009-09-23 | 2011-03-31 | Dikovskiy Aleksander Vladimirovich | Veterinary pharmaceutical composition and method (alternatives) for the prophylaxis and treatment of diseases of the gastrointestinal tract and intoxications of diverse etiology in animals |
| US8231871B2 (en) * | 2004-08-30 | 2012-07-31 | Nikolai Alexandrovich Kiselev | Perorally administrable antimicrobial composition |
-
1998
- 1998-10-14 RU RU98118559A patent/RU2131260C1/en not_active IP Right Cessation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8231871B2 (en) * | 2004-08-30 | 2012-07-31 | Nikolai Alexandrovich Kiselev | Perorally administrable antimicrobial composition |
| WO2011037495A1 (en) * | 2009-09-23 | 2011-03-31 | Dikovskiy Aleksander Vladimirovich | Veterinary pharmaceutical composition and method (alternatives) for the prophylaxis and treatment of diseases of the gastrointestinal tract and intoxications of diverse etiology in animals |
| EP2481413A1 (en) * | 2009-09-23 | 2012-08-01 | Dikovskiy, Aleksander Vladimirovich | Veterinary pharmaceutical composition and method (alternatives) for the prophylaxis and treatment of diseases of the gastrointestinal tract and intoxications of diverse etiology in animals |
| CN102655870A (en) * | 2009-09-23 | 2012-09-05 | 亚历山大·弗拉基米罗维奇·季科夫斯基 | Veterinary pharmaceutical composition for preventing and treating gastrointestinal diseases and various toxicities of animals and method (variants) thereof |
| EP2481413A4 (en) * | 2009-09-23 | 2013-03-20 | Dikovskiy Aleksander Vladimirovich | Veterinary pharmaceutical composition and method (alternatives) for the prophylaxis and treatment of diseases of the gastrointestinal tract and intoxications of diverse etiology in animals |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mallette et al. | Neuromuscular disease in secondary hyperparathyroidism | |
| Bank et al. | Thallium poisoning | |
| Frame et al. | Osteomalacia induced by laxative (phenolphthalein) ingestion | |
| Garg et al. | Intramedullary spinal cysticercosis: response to albendazole: case reports and review of literature | |
| WO1994001099A1 (en) | Pharmaceutical composition having anti-alcohol, radioprotecting and anti-choleraic activity and stimulating energy metabolism, stomach mucous membrane acid-generation and secretion functions | |
| Lauro et al. | Idiopathic muscular infarction in a diabetic patient. Report of a case. | |
| Jain et al. | Efficacy of Activated Charcoal in Reducing Intestinal Gas: A Double--Blind Clinical Trial. | |
| RU2131260C1 (en) | Preparation for treatment of patients with gastroenteric diseases | |
| Tagwireyi et al. | The management of Elephant's Ear poisoning | |
| ZIPRKOWSKI et al. | Hyperkeratosis palmoplantaris with periodontosis (Papillon-Lefèvre) | |
| Carratù et al. | Assessment of small intestinal damage in patients treated with pelvic radiotherapy. | |
| Welch et al. | Prolonged blood concentrations after oral administration of modified penicillin | |
| WO1989005660A1 (en) | Pharmaceutical preparation for individual prophylaxis of venereal diseases and curing urogenital trichomoniasis | |
| Woolridge et al. | Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine | |
| RU2131261C1 (en) | Preparation for treatment of patients with disbacteriosis and gastroenteric diseases | |
| Shearer et al. | Influence of cadmium on caries and the cariostatic properties of fluoride in rats | |
| Gordon et al. | Studies of malabsorption and calcium excretion induced by neomycin sulfate: effect of intestinal site, bile salt, and pancreatic enzymes | |
| Adams et al. | Subacute combined degeneration developing during liver therapy | |
| WO1990004611A1 (en) | Copolymers of vinyl alcohol with vinyl acetate, cross-linked by glutaric dialdehyde, method of obtaining them and a pharmaceutical preparation based thereon | |
| Mann | Physiology and Pathology of the Urine | |
| Kissin et al. | Colchicine myopathy in a patient with familial Mediterranean fever and normal renal function | |
| Toma et al. | Incidence of Yersinia enterocolitica and Y. pseudotuberculosis infections in Canada; 1975 semiannual report. | |
| Askanas et al. | Autosomal dominant syndrome of lipid neuromyopathy with normal carnitine: Successful treatment with long‐chain fatty‐acid‐free diet | |
| Omura et al. | New clinical findings on the longevity gene in disease, health, & longevity: Sirtuin 1 often decreases with advanced age & serious diseases in most parts of the human body, while relatively high & constant Sirtuin 1 regardless of age was first found in the hippocampus of supercentenarians | |
| Steinberg et al. | Successful treatment of dermatitis due to chrysotherapy with adrenocorticotropic hormone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20071015 |
|
| QB4A | License on use of patent |
Effective date: 20080704 |
|
| QB4A | License on use of patent |
Effective date: 20080916 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20081015 |